Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200019/S014

VENTANA MMR RxDx Panel

Ventana Medical Systems · Decision date Oct 8, 2026

FDA DECISIONP200019/S014

What did the FDA approve?

FDA records P200019/S014 as a supplement to PMA P200019, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 8, 2026.

FDA approval order statement

Approval to add a new anti-PMS2 clone, VENTANA anti-PMS2 (SP487) Rabbit Monoclonal Primary Antibody, to the VENTANA MMR RxDx Panel for use on the BenchMark ULTRA and BenchMark ULTRA PLUS platforms
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Oct 8, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P200019/S014
Regulatory pathway
PMA supplement
Product code
QNH
Decision code
APPR
Decision date
Oct 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.

Product code
QNH
FDA device class
3

For the original device and its historical approval scope, see PMA P200019. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200019 · Original PMA

    VENTANA MMR RxDx Panel

  2. P200019/S014 received

    Application receipt date recorded by FDA.

  3. P200019/S014 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P200019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200019

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical SystemsPMA approvalApr 22, 2021FDA

Explore the linked device profile

Other records with product code QNH

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA supplementOct 8, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA approvalAug 15, 2025FDA
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA approvalAug 17, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records